Bausch + Lomb Corporation (BLCO)
| Market Cap | 5.78B |
| Revenue (ttm) | 3.71B |
| Net Income (ttm) | -69.00M |
| Shares Out | 350.00M |
| EPS (ttm) | -0.20 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 488,154 |
| Open | 17.08 |
| Previous Close | 17.23 |
| Day's Range | 16.30 - 17.23 |
| 52-Week Range | 16.01 - 19.18 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About BLCO
Bausch + Lomb is a leading global eye health company dedicated to protecting and enhancing the gift of sight for millions of people around the world—from the moment of birth through every phase of life. Our comprehensive portfolio of over 400 products is fully integrated and built to serve our customers across the full spectrum of their eye health needs throughout their lives. Our iconic brand is built on the deep trust and loyalty of our customers established over our nearly 170-year history. We have a significant global research, developmen...
Financial Performance
Financial StatementsNews
Bausch + Lomb Corporation Files Financial Statements for the First Quarter of 2022
VAUGHAN, ON , May 16, 2022 /PRNewswire/ -- Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb" or the "Company"), a leading global eye health company dedicated to helping people see better to li...
Bausch + Lomb Announces Participation at the RBC Capital Markets Global Healthcare Conference
VAUGHAN, ON , May 13, 2022 /PRNewswire/ -- Bausch + Lomb Corporation, (NYSE/TSX: BLCO) ("Bausch + Lomb"), a leading global eye health company dedicated to helping people see better to live better, today...
New Survey Shows Retina Specialists Believe Suprachoroidal Administration is an Option for Patients With Macular Edem...
Survey Reinforces Need for Innovative Therapies, Including Options Administered Through Suprachoroidal Space VAUGHAN, ON , May 12, 2022 /PRNewswire/ -- Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausc...
Bausch Health And Bausch + Lomb Corporation Announce Closing Of Initial Public Offering Of Bausch + Lomb And Related ...
LAVAL, QC and VAUGHAN, ON , May 10, 2022 /PRNewswire/ -- Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb") and Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") today announced t...
BLCO Stock: 7 Things to Know About the Bausch + Lomb IPO Today
Here's what investors in Bausch + Lomb may want to know about the highly anticipated BLCO stock IPO, which took place today. The post BLCO Stock: 7 Things to Know About the Bausch + Lomb IPO Today appea...
Bausch + Lomb valued at $6.5 billion after stock ticks up in NYSE debut
(Reuters) -Bausch + Lomb was valued at $6.48 billion in its U.S. market debut on Friday as the eye-care company's shares opened nearly 3% above an offer price that was well below the targeted range.
BAUSCH + LOMB CORPORATION LAUNCHES AS A PUBLICLY TRADED COMPANY
Bausch + Lomb Begins Trading under "BLCO" on NYSE and TSX Fully Integrated Eye Health Business Sets Its Sights On Helping the World See Better To Live Better VAUGHAN, ON , May 6, 2022 /PRNewswire/ -- Ba...
Bausch + Lomb stock opens with a slight gain, to value the company at about $6.5 billion
Bausch + Lomb Corp.'s stock BLCO, +5.39% debuted Friday with a slight gain, which helped justify the disappointing pricing overnight of the lenses and medical devices maker's initial public offering. Th...
Busted Bausch + Lomb IPO To Doom IPO Market, Cash Burning Startups
Bausch + Lomb's busted IPO will cost its parent billions in write-downs. It also signals trouble ahead for the IPO market and venture backed startups
Bausch + Lomb prices IPO at $18 a share, below expectations
Bausch + Lomb Corp. priced its IPO at $18 a share Thursday, falling short of expectations as it became the first big company in months to try going public into a turbulent stock market.
Bausch + Lomb Corporation Announces Pricing of IPO
LAVAL, QC and VAUGHAN, ON, May 5, 2022 /PRNewswire/ -- Bausch + Lomb Corporation ("Bausch + Lomb"), a wholly owned subsidiary of Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health"), today ann...
The Wall Street Journal: Bausch + Lomb prices IPO at $18 a share, below expectations
Bausch + Lomb Corp. BLCO, priced its IPO at $18 a share Thursday, falling short of expectations as it became the first big company in months to try going public into a turbulent stock market.
Bausch + Lomb's IPO Will Likely be Priced Below Expectations
In a move that highlights the constraints of the current market, eye care company Bausch + Lomb will likely price its initial public offering (IPO) at the low end of expectations, The Wall Street Journa...
Bausch + Lomb IPO: What You Need to Know
Bausch + Lomb, a well-known leader in eye care, is about to hit Wall Street in what investment bankers almost certainly hope will jump-start a weak initial public offering (IPO) market. Bausch Health Co...
BLCO Stock IPO: When Does Bausch + Lomb Go Public? What Is the Bausch + Lomb IPO Price Range?
Here's what investors may want to know about the upcoming BLCO stock IPO, as Bausch + Lomb is split off from its parent company this week. The post BLCO Stock IPO: When Does Bausch + Lomb Go Public?
IPO Report: U.S. IPO market bracing for second-biggest deal of the year so far in eyecare health company Bausch + Lomb
The U.S. initial public offering market is bracing for what is expected to be the second-biggest deal of the year so far this week, that of eyecare company Bausch & Lomb, which is expected to raise up t...